




















![]()
Q1: 2026-05-11 Earnings Summary
EPS of $0.04 beats by $0.26
|
Revenue of
$27.80M
(18.62% Y/Y)
beats by $998.53K
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT
Company Participants
Seth Yon - President, CEO & Director
Elizabeth Taylor - Chief Financial Officer
Conference Call Participants
Frank Takkinen - Lake Street Capital Markets, LLC, Research Division
Presentation
Operator
Good morning, everyone, and thank you for participating in today's conference call to discuss Sanara MedTech's financial results for the first quarter ended March 31, 2026. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the Investor Relations page of the company's website shortly. The company issued its earnings release yesterday evening. On today's call are Seth Yon, President and Chief Executive Officer; and Elizabeth Taylor, Chief Financial Officer.
Before we begin, I would like to remind everyone that certain statements on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risks and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factors set forth in the company's most recent annual report on Form 10-K.
This call will also include references to certain non-GAAP financial measures. Reconciliations of those non-GAAP measures to the most comparable measures calculated and presented in accordance with GAAP are provided in the earnings release available on the Investor Relations section of the company's website.
I would now like to turn the call over to Mr. Yon. Please go ahead, sir.
Seth Yon
President, CEO & Director
Thank you, operator, and welcome, everyone, to our first quarter 2026 earnings conference call. This was a strong quarter for us, which exceeded our expectations. Q1 2026 was the first full quarter in which we were entirely focus on the surgical market. and
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。